The Reform of the Orphan Drug Assessment System in China

Abstract

This perspective article provides historical background and current considerations of the regulation of rare diseases and orphan drugs in China, presenting the ongoing reform of the orphan drug assessment system in the context of a maze of seemingly convoluted government agencies and regulatory policies that are unique to the fast developing China.